A personalized screening method for substances that improve intestinal environment using PMAS method
A method using L-cysteine to screen personalized probiotics and prebiotics by mimicking individual intestinal environments addresses the lack of personalization in existing treatments, effectively improving intestinal health and treating associated diseases.
Patent Information
- Application Number
- JP2023071270
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-30
- Filing Date
- 2023-04-25
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2040-01-31
AI Technical Summary
Existing probiotics and prebiotics are not personalized to individual microbiomes, leading to inefficacy in improving intestinal health due to low microbiome similarity among humans.
A composition and method using L-cysteine to mimic an individual's intestinal environment in vitro, allowing for the screening of personalized probiotics, prebiotics, foods, and pharmaceuticals by analyzing changes in intestinal flora metabolites and biomarkers.
Enables rapid and accurate verification of personalized intestinal environment improving substances, enhancing microbial diversity, reducing harmful bacteria, and improving overall intestinal health, potentially treating conditions like diarrhea, constipation, enteritis, cancer, obesity, diabetes, and brain-related diseases.
Smart Images

Figure 0007587872000002 
Figure 0007587872000003 
Figure 0007587872000004
Abstract
Description
[Technical field]
[0001] The present application relates to a composition for screening for substances that improve intestinal environment, and a screening method using said composition. [Background technology]
[0002] Genome refers to the genes contained in chromosomes, microbiota refers to the microbial community in the environment, and microbiome refers to the genetic body of the total microbial community in the environment. Here, microbiome can mean the combination of genome and microbiota.
[0003] The intestinal microbiota is known to play an important role in maintaining homeostasis of the host, such as the human immune system and metabolic substances. Chemical signals are exchanged between the intestinal microbiota and the host, and the expression of immune cells, production of neurotransmitters, and short chain fatty acids (SCFAs) by the intestinal microbiota have a significant impact on the host's internal systems.
[0004] Probiotics / prebiotics balance the host's imbalanced intestinal flora, and the resulting metabolic products of healthy intestinal flora promote the host's health. Existing probiotics, like general medicines, provide the same dose and similar species of bacteria to all humans.
[0005] However, there is increasing recognition and research that probiotics must be personalized, as microbiome similarity between humans is less than 50%.
[0006] Therefore, the present invention proposes a method for verifying the compatibility of an individual's intestinal flora with various foods, including probiotics or prebiotics, that aim to regulate and improve the intestinal flora, as well as health functional foods and pharmaceuticals. Summary of the Invention [Problem to be solved by the invention]
[0007] The present application relates to a composition for screening for substances that improve the intestinal environment, a screening method using the composition, and a method for providing information for disease diagnosis through detection of biomarkers in the intestine.
[0008] However, the problems to be solved by the present application are not limited to those mentioned above, and other problems not mentioned will be clearly understood by those of ordinary skill in the art from the following description. [Means for solving the problem]
[0009] A first aspect of the present application provides a composition for screening for substances that improve the intestinal environment, comprising L-cysteine.
[0010] A second aspect of the present application provides a method for screening for substances that improve intestinal environment, comprising the steps of: (a) mixing a sample obtained from an individual with the composition of paragraph 1; (b) treating and culturing the mixture of step (a) with one or more candidate substances for improving intestinal environment; and (c) analyzing the culture of step (b). Effect of the Invention
[0011] According to the examples and embodiments of the present application, a method for verifying personalized probiotics, prebiotics, foods, health functional foods, and pharmaceuticals under in vitro conditions based on the intestinal microbiota and intestinal microbiota metabolites is provided, thereby providing an effective analytical method for screening candidate effective substances for improving the intestinal microbiota in a personalized manner.
[0012] The method according to the present application can be applied to a biomarker-based screening system, and personalized candidate substances can be rapidly verified by a personalized and effective screening method. [Brief description of the drawings]
[0013] [Figure 1] 1 shows an example diagram of a personalized probiotics, prebiotics, food, health functional food and medicine screening process using PMAS technique. [Diagram 2] 1 shows an example diagram for explaining sample analysis by the PMAS technique. [Diagram 3] 1 shows an example diagram for interpreting sample analysis results by PMAS technique. [Figure 4] This shows an example of selecting candidate substances for personalized probiotics, prebiotics, foods, health functional foods, and pharmaceuticals through the analytical results obtained after conducting PMAS. [Diagram 5] FIG. 1 shows the results of an analysis of short-chain fatty acid content depending on the composition of PMAS medium. [Figure 6] FIG. 1 shows the results of an analysis of short-chain fatty acid content according to the culture time of PMAS. [Figure 7] FIG. 1 illustrates the repeatability of the PMAS technique of the present application. [Figure 8] FIG. 1 shows the consistency with clinical results of the PMAS technique of the present application. [Figure 9] 1 shows an example of the configuration of a plate well when performing PMAS of the present invention. [Figure 10] 1 shows an example of an analysis of changes in butyric acid amount by the PMAS test of the present application. [Figure 11] 1 shows an example diagram of an analysis of changes in microbial diversity using the PMAS test of the present application. [Figure 12] 1 shows an example of a correlation analysis between microbial composition and butyric acid by the PMAS test of the present application. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Throughout the specification of this application, when a part "comprises" a certain component, this means that it may further include other components, not excluding other components, unless otherwise specified. The terms "about," "substantially," and the like, which are used throughout the specification of this application, are used to mean a numerical value or a close approximation of a numerical value when the manufacturing and material tolerances inherent in the mentioned meaning are presented, and are used to prevent unscrupulous infringers from unfairly taking advantage of the disclosure in which precise or absolute numerical values are mentioned to aid in the understanding of this application.
[0015] Throughout the specification of this application, the term "combination(s) of" contained in a Markush form expression means a mixture or combination of one or more selected from the group of elements set forth in the Markush form expression, and is meant to include one or more selected from the group of elements set forth above.
[0016] Throughout the specification of this application, the statement "A and / or B" means "A or B, or A and B."
[0017] Hereinafter, embodiments and examples of the present application will be described in detail with reference to the accompanying drawings, but the present application is not limited to the embodiments and examples and drawings.
[0018] A first aspect of the present application provides a composition for screening for substances that improve the intestinal environment, comprising L-cysteine.
[0019] In one embodiment of the present application, the composition is for selecting a candidate substance capable of improving the intestinal environment, and specifically, it may be understood as a composition used in a series of processes for checking the progress of improvement of the intestinal environment and evaluating whether the candidate substance has been able to improve the intestinal environment, but is not particularly limited thereto.
[0020] In one embodiment of the present application, the composition is a composition for mimicking an individual user's internal environment in vitro, and the use of the composition can accurately and efficiently determine whether a candidate substance improves the intestinal environment even under in vitro conditions, and therefore can be usefully used for screening substances that improve personalized intestinal environments.
[0021] The term "improvement of intestinal environment" used throughout the specification of this application means favorably changing the composition of intestinal microorganisms and metabolites of the microorganisms, etc., and means that by improving the intestinal environment, beneficial bacteria in the intestines and metabolites of beneficial bacteria are increased, which exhibits effects such as vitamin synthesis, improved digestion and absorption, infection prevention, and immune strengthening, and harmful bacteria and metabolites of harmful bacteria are decreased, which reduces intestinal putrefaction, bacterial toxins, and carcinogens, etc. In addition, by improving the intestinal environment, not only intestinal diseases such as diarrhea, constipation, and enteritis, but also cancer, obesity, diabetes, and brain-related diseases can be prevented or treated.
[0022] In one embodiment of the present application, the improvement of the intestinal environment may be one or more selected from the group consisting of an increase in the microbial diversity of the intestinal flora, a decrease in endotoxins and hydrogen sulfide derived from intestinal microorganisms, an increase in beneficial metabolites derived from the intestinal flora, an increase or decrease in short-chain fatty acids, an increase in the types and number of beneficial bacteria, and a decrease in the types and number of harmful bacteria, but is not limited thereto.
[0023] The term "L-cysteine" used throughout the specification of this application is one of the amino acid supplements, which plays an important role in metabolism as a component of glutathione in the body, and is also used to prevent browning of fruit juice and the like and to prevent the oxidation of vitamin C.
[0024] In one embodiment of the present application, the L-cysteine may be contained at a concentration of 0.001% (w / v) to 5% (w / v), specifically, 0.01% (w / v) to 0.1% (w / v), but is not limited thereto.
[0025] In one embodiment of the present application, the L-cysteine may be included in the composition for screening intestinal environment improving substances in various types of dosage forms or in the form of a salt, and specifically, the L-cysteine may be L-cysteine hydrochloride, but is not limited thereto.
[0026] In one embodiment of the present application, the composition may further include, but is not limited to, mucin.
[0027] The term "mucin" used throughout the specification of this application is a mucus substance secreted from the mucosa, also called mucusin or mucin, and includes submandibular gland mucin, gastric mucosa mucin, small intestine mucin, etc. Mucin is a type of glycoprotein, and is known to be one of the energy sources that can be utilized by intestinal microorganisms as a carbon source and nitrogen source.
[0028] In one embodiment of the present application, the mucin may be contained at a concentration of 0.01% (w / v) to 5% (w / v), specifically, 0.1% (w / v) to 1% (w / v), but is not limited thereto.
[0029] In one embodiment of the present application, the composition may be free of nutritional substances other than mucin, and may be specifically characterized as being free of nitrogen sources and / or carbon sources such as proteins and carbohydrates.
[0030] In one embodiment of the present application, the protein serving as the carbon source and nitrogen source may be one or more of tryptone, peptone, and yeast extract, but is not limited thereto, and may specifically be tryptone.
[0031] In one embodiment of the present application, the carbohydrate serving as the carbon source may be one or more of monosaccharides such as glucose, fructose, and galactose, and disaccharides such as maltose and lactose, but is not limited thereto, and may specifically be glucose.
[0032] In one embodiment of the present application, the composition may be free of glucose and tryptone, but is not limited thereto.
[0033] In one embodiment of the present application, the composition may include one or more selected from the group consisting of sodium chloride (NaCl), sodium carbonate (NaHCO), KCl (potassium chloride), and hemin. Specifically, the sodium chloride may be included at a concentration of 10 to 100 mM, the sodium carbonate may be included at a concentration of 10 to 100 mM, the potassium chloride may be included at a concentration of 1 to 30 mM, and the hemin may be included at a concentration of 1×10 -6 g / L~1×10 -4 It may be present at a concentration of g / L, but is not limited thereto.
[0034] In one embodiment of the present application, the composition may be, but is not limited to, a culture medium composition.
[0035] In one embodiment of the present application, the intestinal environment improving substance may be one or more selected from the group consisting of probiotics, prebiotics, foods, health functional foods, and medicines, but is not limited thereto.
[0036] The term "probiotics" used throughout the present specification means bacteria that enter the body and have a beneficial effect on health. Specifically, probiotics that reach the intestine and grow in the intestinal mucosa produce lactic acid to acidify the intestinal environment, reducing the number of harmful bacteria that cannot tolerate an acidic environment and further increasing the number of beneficial bacteria that can grow well in an acidic environment, thereby making the intestinal environment healthy. The probiotics may include, but are not limited to, Lactobacillus, Lactococcus, Enterococcus, Streptococcus, Bifidobacterium, etc., and the probiotics may be manufactured in the form of fermented milk, granules, powder, etc. containing the above strains.
[0037] The term "prebiotics" used throughout the specification of this application refers to ingredients that activate probiotics, which are beneficial bacteria, while at the same time suppressing harmful bacteria in the intestines, and play a role in creating an intestinal environment in which probiotics can grow well. In addition, the prebiotics act as food that is broken down and used as an energy source for the production of probiotics, and since they are sugars that are not absorbed by the body, they move directly to the intestine without being absorbed in the small intestine, where they not only become food for lactic acid bacteria, but also have the effect of reducing harmful bacteria.
[0038] In one embodiment of the present application, the composition may be characterized by embodying an intestinal environment under in vitro conditions.
[0039] A second aspect of the present application provides a method for screening for substances that improve intestinal environment, comprising the steps of (a) mixing a sample obtained from an individual with the composition for screening for substances that improve intestinal environment, (b) treating the mixture of step (a) with one or more candidate substances for improving intestinal environment, and culturing the mixture, and (c) analyzing the culture of step (b). The contents that overlap with those of the first aspect of the present application also apply to the method of the second aspect of the present application.
[0040] In an embodiment of the present application, the method may be a method for screening a substance for preventing and treating diseases caused by intestinal dysbiosis.
[0041] In one embodiment of the present application, the method may be understood as a series of processes in which a candidate substance capable of improving the intestinal environment is treated through a series of processes in a sample obtained from an individual in need of intestinal environment improvement, and then the progress of the intestinal environment improvement is checked to evaluate whether the candidate substance can improve the intestinal environment, but is not limited thereto. Specifically, by checking the degree of improvement of the intestinal environment, if the intestinal environment is improved, the candidate substance may be determined to be an intestinal environment improving substance.
[0042] In one embodiment of the present application, the method may be characterized in that it is carried out under in vitro conditions.
[0043] The term "individual" as used throughout the specification of this application means any living organism that has an abnormal intestinal environment, that has or may have a disease caused by an abnormal intestinal environment, or that needs to have its intestinal environment improved, and specific examples may include, without limitation, mice, monkeys, cows, pigs, mini-pigs, livestock, mammals including humans, birds, farmed fish, etc.
[0044] The term "sample" as used throughout the specification of this application means a substance derived from the individual, and specifically may be cells, urine, feces, etc., but the type is not limited thereto, so long as it is possible to detect substances present in the intestine, such as intestinal flora, intestinal microbial metabolites, endotoxins, and short-chain fatty acids.
[0045] In one embodiment of the present application, the method may include, but is not limited to, a sample preparation process, a sample pretreatment process, a sample analysis process, a data analysis process, and a process of selecting a personalized intestinal environment improving substance based on the derived data.
[0046] In one embodiment of the present application, the method may be a high-throughput screening method, where the high-throughput means being faster than the currently known intestinal microbiota analysis methods and intestinal environment analysis methods, and specifically, the high-throughput may mean 12 hours to 48 hours, more specifically, 18 hours to 24 hours, but is not limited thereto.
[0047] In one embodiment of the present application, the culture in step (b) may be performed for 12 to 48 hours, specifically, for 18 to 24 hours, but is not limited thereto.
[0048] In one embodiment of the present application, the method may be performed under anaerobic conditions, specifically, the culturing in step (b) of the method may be performed under anaerobic conditions.
[0049] In one embodiment of the present application, the candidate substance for improving intestinal environment may be one or more selected from the group consisting of probiotics, prebiotics, foods, health functional foods, and pharmaceuticals, but is not limited thereto.
[0050] In one embodiment of the present application, analyzing the culture in step (c) is to analyze whether the intestinal environment has been improved, and specifically, the type, content and / or concentration of one or more of endotoxin, hydrogen sulfide as a result of abnormal intestinal fermentation, short-chain fatty acids (SCFAs), and metabolites derived from the intestinal flora contained in the culture may be analyzed, and the type, content and / or concentration that changes when the sample is treated with a candidate substance may be analyzed.
[0051] The term "endotoxin" as used throughout this specification refers to a toxic substance found inside bacterial cells, such as an antigen composed of a complex of proteins, polysaccharides, and lipids.
[0052] In one embodiment of the present application, the endotoxin may include, but is not limited to, Lipopolysaccharide (LPS), and the LPS may specifically be Gram negative, pro-inflammatory.
[0053] The term "short-chain fatty acid (SCFA)" used throughout the specification of this application means a short fatty acid having six or less carbon atoms, and is a typical metabolic product produced by intestinal microorganisms. Short-chain fatty acids have useful functions in the body, such as increasing immunity, stabilizing intestinal lymphocytes, lowering insulin signals, and stimulating sympathetic nerves.
[0054] In one embodiment of the present application, the short chain fatty acid may include, but is not limited to, one or more selected from the group consisting of formate, acetic acid, propionate, butyrate, isobutyrate, valerate, and isovalerate.
[0055] In one embodiment of the present application, analyzing the culture in step (c) may be, but is not limited to, analyzing changes in the type, content, concentration and / or diversity of bacteria contained in the intestinal flora of the culture.
[0056] In one embodiment of the present application, the intestinal flora may include beneficial and harmful intestinal bacteria. Specifically, the beneficial intestinal bacteria may include Lactobacillus and Bifidobacteriaum, and the harmful intestinal bacteria may include, but are not limited to, Proteobacteria and Clostridium difficile.
[0057] In one embodiment of the present application, methods for analyzing endotoxin, hydrogen sulfide as a result of abnormal intestinal fermentation, short-chain fatty acids (SCFAs), and metabolites derived from intestinal flora, intestinal flora, and intestinal microbial diversity may use various analytical methods available to ordinary skilled artisans for the above analyses, such as absorbance analysis, chromatography analysis, genetic analysis such as next generation sequencing, and metagenomic analysis.
[0058] In one embodiment of the present application, the method may further include a step of comparing the analysis results of step (c) with the analysis results of a control group to select a candidate substance that increases the content of short-chain fatty acids, increases the types and content of beneficial bacteria in the intestinal flora, decreases the content of endotoxins and hydrogen sulfide, or decreases the types and content of harmful bacteria in the intestinal flora.
[0059] The term "control group" as used throughout the specification of this application refers to samples or data that can be compared with changes in the intestinal environment due to treatment with a candidate substance for improving the intestinal environment (such as short-chain fatty acids, intestinal flora, endotoxins, hydrogen sulfide, and types, concentrations, and / or contents of intestinal microbial metabolites), and is not limited to these. Specifically, it may include samples from individuals that have not received any treatment, or samples from individuals that have been treated only with a control substance such as vehicle, saline, or DMSO, but is not limited to these.
[0060] In one embodiment of the present application, the method mimics an individual user's internal environment, including intestinal flora, temperature, humidity, and motion, in vitro, and is capable of analyzing a predetermined number of probiotics, prebiotics, foods, health functional foods, and drug candidates in parallel, thereby enabling rapid screening of the most effective candidate substances for improving personalized intestinal flora.
[0061] In one embodiment of the present application, the method may involve in-vitro pretreatment of fecal samples from humans and various animals, which can most easily represent the intestinal microbial environment in the body, treatment with a candidate substance for improving the intestinal microbiota, and verification of functionality and mode of action of the candidate substance, and examining the taxonomic identification, microbial safety, and microbial functionality of the intestinal microbiota resulting from the candidate substance. In this way, efficient personalized probiotics screening may be performed through a fast screening method containing individual's feces and special media and analysis of the fecal-derived microbiome and metabolites.
[0062] In one embodiment of the present application, the gist of the present application is to propose a method for screening personalized probiotics, prebiotics, foods, health functional foods, and medicines using a sample such as feces. Hereinafter, the method according to the present application will be described as PMAS (Personalized Pharmaceutical Meta-Analysis Screening).
[0063] A third aspect of the present application provides a method for providing information for diagnosing diseases caused by intestinal dysbiosis. The contents overlapping with the first and second aspects of the present application also apply to the method of the third aspect of the present application.
[0064] In one embodiment of the present application, the method may include a step of detecting a biomarker for diagnosing a disease caused by intestinal dysbiosis from a sample obtained from an individual, and the method may include a sample preparation process, a sample pretreatment process, a sample analysis process, a data analysis process, and a process of diagnosing the disease based on the derived data.
[0065] In one embodiment of the present application, the biomarker may be a substance detected in the intestine, and specifically may include, but is not limited to, intestinal flora, endotoxin, hydrogen sulfide, intestinal microbial metabolites, short-chain fatty acids, etc.
[0066] Examples of the present application are described in detail below, but the present application is not limited thereto.
[0067] [Example] Example 1. Overall process of personalized candidate substance screening system using PMAS (Personalized Pharmaceutical Meta-Analysis Screening) technique This application relates to compositions and methods for screening personalized probiotics, foods, health functional foods, pharmaceuticals, etc. under in vitro conditions using samples such as an individual's feces, and in this application, the screening system is described as PMAS (Personalized Pharmaceutical Meta-Analysis Screening).
[0068] FIG. 1 shows an example of a screening process for personalized probiotics, prebiotics, foods, health functional foods, and medicines using the PMAS technique. The overall process of the screening system of the present application will be described below using FIG. 1.
[0069] (1) Sample preparation Human or animal feces and PMAS medium are mixed in a ratio of 1:12, homogenized using a stomacher, and the fecal residue is removed using a filter net. Prior to the treatment of probiotics, foods, health functional foods, and drug candidates, the mixture of feces and medium is reduced in an anaerobic chamber for 4 hours.
[0070] (2) Dispensing the feces-medium mixture The homogenized mixture of feces and medium in the anaerobic chamber is dispensed in equal amounts into culture plates, such as 96-well plates.
[0071] (3) Processing of candidate substances The probiotics, foods, health functional foods and drug candidates to be treated are suspended in sterilized 1xPBS, and the concentration and amount are homogenized and dispensed into the culture plates containing the feces-culture medium mixture.
[0072] (4) Anaerobic culture Each experimental group is cultured by fermentation by culturing the plates under anaerobic conditions with temperature, humidity and motion similar to the intestinal environment.
[0073] (5) Sample analysis The cultured experimental groups are centrifuged to separate the supernatant and sediment (pallet), and the supernatant is then analyzed for metabolites, short-chain fatty acids, toxic substances, etc., while the sediment is analyzed for intestinal flora.
[0074] Example 2. Sample analysis process using PMAS technique In the PMAS technique of Example 1, an example of the process of the sample analysis step is shown in FIG. 2 and FIG.
[0075] Specifically, after the incubation of the experimental groups treated with the candidate substances is completed, the supernatant obtained by centrifuging each of the cultured experimental groups is analyzed for toxic substances such as hydrogen sulfide and bacterial LPS (endotoxin) and microbial metabolites such as short-chain fatty acids by absorbance measurement analysis and chromatography analysis, and the precipitate (pallet) obtained by centrifugation is analyzed for culture-independent intestinal flora analysis. For example, the change in the amount of hydrogen sulfide produced by incubation can be measured using the methylene blue method, which reacts N,N-dimethyl-p-phenylene-diamine with ferric chloride (FeCl3), and the level of endotoxin, which is one of the factors that promote inflammatory responses, can be measured by endotoxin assay kit analysis. In addition, short-chain fatty acids such as acetate, propionate, and butyrate, which are microbial metabolites, can be analyzed by gas chromatography analysis. The intestinal flora may be analyzed by a genome-based analysis method such as real-time PCR using bacteria-specific primers proposed in the GULDA method or metagenome analysis such as next generation sequencing after extracting all the genomes in the sample. That is, the method according to the present application may screen for a candidate substance for improving personalized intestinal flora based on at least one of a toxic substance analysis, an analysis of metabolites derived from intestinal flora including short chain fatty acids, and an intestinal flora analysis, and specifically, a candidate substance for improving personalized intestinal flora may be screened by searching for a candidate substance with a reduced level of endotoxin by an analysis of toxic substances including endotoxin and hydrogen sulfide, confirming a change in a preset target short chain fatty acid by an analysis of short chain fatty acids, and confirming a change in the intestinal flora before and after treatment with the candidate substance by an intestinal flora analysis.
[0076] Example 3. Screening process of personalized candidate substances using sample analysis results of PMAS technique FIG. 4 shows an example of a process for screening personalized probiotics, foods, health functional foods, and medicines based on the sample analysis results of Example 2.
[0077] Specifically, the results of the analysis after PMAS are evaluated to determine whether the treated candidate substance has the effect of improving the intestinal flora. First, if the supernatant does not remain at the minimum amount required for analysis when centrifuging after the end of fermentation and culture, PMAS treatment and culture are performed again to ensure that there is a sufficient amount of supernatant to be used for analysis. Among these, if the amount of toxic substances increases, the total amount of short-chain fatty acids is outside the normal range, and harmful bacteria has significantly decreased compared to before treatment, this is considered to be an imbalance in the intestinal flora induced by the treatment substance, and it is excluded from the selection target. However, if the number of beneficial bacteria has decreased, it is excluded from the selection target only if the diversity of the entire intestinal flora examined by metagenome analysis using next generation sequencing, etc. has significantly decreased. In addition to the above, when screening is to be performed based on the effects of probiotics, foods, health functional foods, and drug candidate substances on specific biomarkers in the intestine, the biomarker-related analysis is performed and selected only if the substances pass the above-mentioned selection criteria.
[0078] That is, the present invention may screen for a candidate substance for improving a personalized intestinal flora based on at least one of an analysis of toxic substances including endotoxin and hydrogen sulfide, an analysis of metabolites derived from intestinal flora including short chain fatty acids, an analysis of harmful intestinal bacteria including Proteobacteria and Clostridium difficile, and an analysis of beneficial intestinal bacteria including Lactobacillus and Bifidobacteriaum. Specifically, the present invention may screen for a candidate substance for improving a personalized intestinal flora by searching for a candidate substance with a reduced level of a toxic substance through an analysis of toxic substances including endotoxin and hydrogen sulfide, confirming a change in a preset target short chain fatty acid through an SCFA analysis, and confirming the degree of increase or decrease in harmful intestinal bacteria and beneficial intestinal bacteria through an analysis of harmful intestinal bacteria and the above-mentioned analysis of beneficial intestinal bacteria. For example, the present application may select an experimental group in which the proportion of butyric acid in the total short-chain fatty acids increases most significantly if the production of toxic substances does not increase significantly, the total amount of short-chain fatty acids is within the normal range, harmful bacteria does not increase significantly, beneficial bacteria does not decrease significantly, or beneficial bacteria decreases significantly but the diversity of intestinal microbiota increases, and screen personalized probiotics, foods, health functional foods, and medicines. Of course, the present invention may select an experimental group in which the production of toxic substances does not increase significantly, the total amount of SCFAs is within the normal range, harmful bacteria does not increase significantly, beneficial bacteria does not decrease significantly, or beneficial bacteria decreases significantly but the diversity of intestinal microbiota increases, and additional intestinal specific biomarker analysis is required, and the increase / decrease and presence / absence of specific biomarkers may be additionally analyzed, and an experimental group in which the specific biomarkers are affected as a result of the PMAS substance treatment may be selected according to the analysis results, and personalized probiotics, prebiotics, foods, health functional foods, and medicines may be screened.
[0079] Experimental example 1. Confirmation of medium creation using PMAS technique In order to confirm the optimal composition of the PMAS medium for use in the PMAS technique of Example 1 above, the following experiment was carried out.
[0080] Specifically, fecal samples were mixed with media containing various substance compositions shown in Table 1 below at a ratio of 1:12 (w / v), and then homogenized using a Stomacher.
[0081] [Table 1]
[0082] The fecal samples were then dispensed into a 96-well plate, and the control group was not treated with any substance, while the prebiotic group was treated with a prebiotic preparation (culture medium:fecal sample:prebiotic = 1:12:2 (w / v)). After culturing in an anaerobic environment at 37°C for 18 hours, the butyric acid, propionic acid and acetic acid contents of the control group and the prebiotic group were compared and analyzed.
[0083] As a result, in Test 1 and Test 3, despite the treatment with prebiotics, which are known to be activated by intestinal microorganisms to produce short-chain fatty acids, there was no change in the contents of butyric acid, propionic acid and acetic acid, whereas in Test 4, it was confirmed that the contents of butyric acid, propionic acid and acetic acid actually decreased when the prebiotics were treated (Figure 5).
[0084] In contrast, in the cases of Test2 and Test5, it was confirmed that the short-chain fatty acid content generally increased in the groups treated with prebiotics (Figure 5). In the case of Test5, the absolute amount (mM) of short-chain fatty acids was greater than that of Test2, making analysis easier. In the following experimental example, an experiment was performed using a medium having the composition of Test5.
[0085] Considering the above results overall, it can be seen that the composition containing L-cysteine hydrochloride but no nutritional components (Test 2) and the composition containing L-cysteine hydrochloride and mucin (Test 5) actually produced the expected results from prebiotic treatment. Therefore, by using a medium having a composition containing L-cysteine hydrochloride or L-cysteine hydrochloride and mucin but not containing carbohydrates such as glucose and proteins such as tryptone, it is possible to rapidly and accurately confirm changes in the intestinal environment caused by treatment with a candidate substance by similarly reproducing the intestinal environment under in vitro conditions.
[0086] Experimental Example 2. Setting incubation time for screening substances that improve the intestinal environment In order to confirm the optimal incubation time in the anaerobic incubation step in the PMAS technique of Example 1 above, the following experiment was carried out.
[0087] Specifically, the experiment was conducted in the same manner as in Experimental Example 1 above, except that the anaerobic culture time was set to 0 hours, 18 hours, 21 hours, 24 hours, 40 hours, and 48 hours, and the contents of butyric acid, propionic acid, and acetic acid after culture were measured.
[0088] As a result, it was confirmed that in both the control and prebiotic groups, the content of short-chain fatty acids increased rapidly up to 18 hours of culture, after which it entered a plateau (Figure 6).
[0089] Based on the above results, the PMAS technique of this application is used to quickly find candidates. For quality screening, it appears that an anaerobic incubation time of 18 hours is the most efficient.
[0090] Experimental Example 3. Confirmation of the effectiveness of the personalized candidate substance screening method using PMAS technique In order to confirm the validity of using the PMAS technique of the present application to accurately screen candidate substances for personalization by creating an individual's intestinal environment under in vitro conditions, the following experiment was conducted.
[0091] (1) Check repeatability In order to confirm whether the analysis results using the PMAS technique of the present invention can be repeatedly reproduced for the same specimen, the following experiment was carried out.
[0092] Specifically, to confirm the repeatability of PMAS analysis results for fecal samples (A1-A4, B1-B3) collected on different dates from different humans A and B, the amount of butyric acid was measured for a control group that was not treated with any substance and experimental groups that were treated with five candidate substances, and the butyric acid quantification values for the groups treated with the five candidate substances were divided by the butyric acid quantification values for each control group to determine the increase or decrease in butyric acid during treatment with the candidate substances for each sample. Next, the results of treatment with the five candidate substances for each sample at each time point were analyzed using Pearson's correlation (the closer the correlation coefficient is to 1, the more similar the results are).
[0093] As a result, it was confirmed that the PMAS analysis results for fecal samples collected from the same individual showed a fairly similar tendency (correlation coefficient of 0.8 or more), but showed differences between the PMAS analysis results of different individuals (Figure 7). Looking at the above results overall, it can be seen that by using the PMAS technique of the present application, the results of the same human samples can be repeatedly reproduced even under in vitro conditions.
[0094] (2) Confirmation of consistency with clinical results In order to confirm whether the analysis results using the PMAS technique of the present invention are identical to actual clinical results, the following experiment was carried out.
[0095] Specifically, fecal samples were obtained from 24 individuals, and the fecal samples were analyzed for the presence or absence of an increase or decrease in short chain fatty acid content in response to probiotic A treatment using the PMAS technique of the present invention.
[0096] Next, after the 24 people actually took Probiotic A, the presence or absence of an increase or decrease in short-chain fatty acids in fecal samples before and after taking the drug was clinically confirmed, and the clinical results were compared and analyzed with the PMAS results.
[0097] As a result, it was confirmed that 12 out of the 24 people had an increase in short-chain fatty acids in their feces after taking Probiotic A, while the remaining 12 people had a decrease in short-chain fatty acids. In addition, when the effects of Probiotic A were confirmed using PMAS techniques, it was confirmed that short-chain fatty acids increased in a total of 14 samples, and decreased in 10 samples (Figure 8), and the above results were analyzed as follows.
[0098] 1) If short-chain fatty acids increase as a result of PMAS, and short-chain fatty acids actually increase, the result is -11 / 14=0.79
[0099] 2) If the PMAS results show a decrease in short-chain fatty acids, and the actual decrease is also -9 / 10=0.9
[0100] 3) Among people whose short-chain fatty acids actually increased, if their PMAS results also showed an increase in short-chain fatty acids, the result would be -11 / 12 = 0.92
[0101] 4) Among people whose short-chain fatty acids actually decreased, if the PMAS results also showed a decrease in short-chain fatty acids, then -9 / 12=0.75
[0102] 5) False negative for increased short-chain fatty acids -1-0.92=0.08
[0103] 6) False positive for an increase in short-chain fatty acids - 1 - 0.75 = 0.15
[0104] 7) If we assume that the prevalence (the frequency with which short-chain fatty acids actually increase after taking probiotic A) is 0.5, the PPV is (0.92 x 0.5) / (0.92 x 0.5 + (1-0.75) x (1-0.5)) = 0.86
[0105] Considering the above results comprehensively, the PMAS technique of the present application can reproduce repeatability within the same individual even under in vitro conditions, and obtains results very similar to those in actual clinical practice. Based on this, it can be seen that the PMAS technique can reproduce the intestinal environment very similarly, and that by utilizing this, it is possible to quickly and efficiently screen for intestinal environment improving substances that have excellent effects on individuals.
[0106] Experimental Example 4. Specific implementation of personalized candidate substance screening system using PMAS technique By using the PMAS technique described in the above Examples 1 to 3 and Experimental Examples 1 to 3, the intestinal environment of an individual can be rapidly and accurately analyzed under in vitro conditions, and a candidate substance capable of improving the intestinal environment can be screened based on the analysis. The following description is an example of a screening system using the PMAS technique, and a person having ordinary skill in the art can make various modifications and variations from the above description. For example, suitable results can be achieved even if the described techniques are performed in a different order from the described method, and / or the components of the described system, structure, device, process, etc. are combined or combined in a different form from the described method, or are replaced or substituted by other components or equivalents.
[0107] (1) Preparation of fecal-medium mixture and treatment of candidate substances Eight different human fecal samples were mixed and homogenized with PMAS medium and distributed in equal amounts onto a 96-well plate (horizontal axis), and different candidate substances were treated vertically into the 96-well plate into which the fecal samples were distributed (Figure 9).
[0108] The control group (standard) is used to judge the degree of improvement of the intestinal environment by comparing the analytical values measured after the PMAS test. Among the reference treatments, the antibiotic mixture (ABX) was used as a negative control group to create an environment where the activity of microorganisms in the feces was rapidly reduced, and Clostridium butyricum (CB, a bacterial strain that produces butyric acid itself) was used as a positive control group to create an environment where butyric acid, a substance that is effective in judging whether the intestinal environment has improved, was clearly increased. In addition, the remaining bacterial strains, LB, EF, and BF, are candidate substances to be tested, and different numbers indicate different bacterial strains.
[0109] (2) PMAS analysis results – Analysis of changes in butyric acid content Using the same method as described above (1), PMAS tests were performed using fecal samples from 100 different adults, and the resulting changes in butyric acid levels were analyzed and shown in Figure 10.
[0110] Specifically, each row in the heat map in Figure 10 represents a fecal sample, and after PMAS, if the amount of butyric acid increased compared to the control (baseline) well, it was displayed in red, and if it decreased, it was displayed in blue.
[0111] As a result, it was confirmed that butyric acid increased significantly when CB treatment, the positive control for butyric acid, was used compared to the other treatments, and that butyric acid decreased significantly when ABX treatment, the negative control, was used compared to the other treatments (a decrease in the microbial metabolite butyric acid due to a decrease in microbial activity).
[0112] In addition, the candidate substances in the test group were bacteria of the Lactobacillus, Bifidobacteria, and Enterococcus families, and although they cannot produce butyric acid on their own, it was confirmed that butyric acid increased in certain feces when these strains were treated. From this, it can be inferred that in some cases (in the case of certain fecal samples), the treatment of certain candidate substances in the PMAS environment induces changes in the activity of other microorganisms in the sample (in the direction of increasing butyric acid).
[0113] Considering the above results collectively, it was confirmed that the PMAS technique showed different environmental changes due to treatment with candidate substances for each fecal sample, which indicates that it is possible to screen for microbial-based candidate substances for improving the intestinal environment in each fecal sample.
[0114] (3) PMAS analysis results – Changes in gut microbial diversity Using the same method as described above (1), PMAS tests were performed using fecal samples from 100 different adults, and the changes in intestinal microbial diversity for some of the samples were analyzed and shown in Figure 11.
[0115] Specifically, each row in the heat map in Figure 11 represents a fecal sample, and after PMAS, if microbial diversity increased compared to the control (baseline) wells, it was displayed in red, and if it decreased, it was displayed in blue.
[0116] As a result, it was confirmed that the candidate treatment substances that increased or decreased the microbial diversity were different for each fecal sample, and that the effects of each candidate substance were different for different fecal samples. It was also confirmed that the microbial diversity was definitely decreased in the ABX treatment compared to the other treatment groups.
[0117] (4) PMAS analysis results - Correlation between the microbial composition of the initial fecal sample and the change in butyric acid content after PMAS testing Using the same method as above (1), PMAS tests were performed using fecal samples from 100 different adults, and the correlation between the microbial composition of the initial fecal samples and the change in butyric acid content after the PMAS test was analyzed, and the results are shown in Figure 12.
[0118] Specifically, Figure 12A is a graph showing the "butyric acid change results for different candidate substance treatments (multivariate, 10 results excluding the reference control group)" of each fecal sample after PMAS on one plane by PCA analysis (x-axis is PC1, y-axis is PC2, representing 90.36% of all data, dots on the graph represent each fecal sample), and the category initial faecal microbiota PC1 is the PC1 score calculated by weighted UniFrac distance for the gut microbiota results (initial faecal microbiota) before PMAS of the feces used in PMAS. Also, Figure 12B is a graph showing the correlation between the principal component PC1 of the butyric acid change results of each fecal sample after PMAS and the beta diversity PC1 of the gut microbiota change of each fecal sample before PMAS.
[0119] Based on the above results, it can be seen that the butyric acid change results of each fecal sample after PMAS have a significant correlation with the microbial analysis results before PMAS of that fecal sample. In other words, it can be inferred that the different butyric acid change patterns after PMAS in each fecal sample are due to the different distribution and composition of microorganisms in the feces (rather than random changes).
[0120] The above description of the present application is for illustrative purposes only, and a person having ordinary skill in the art to which the present application pertains should understand that the present application can be easily modified into other specific forms without changing the technical idea or essential features of the present application. Therefore, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting. For example, each component described as a single type may be implemented in a distributed form, and similarly, each component described as a distributed type may be implemented in a combined form.
[0121] The scope of the present application is indicated by the claims set forth below rather than by the above detailed description, and all modifications and variations derived from the meaning and scope of the claims, as well as their equivalent concepts, should be construed as being included within the scope of the present application.
Claims
1. (a) mixing a sample obtained from an individual with a composition for screening for substances that improve intestinal environment; (b) treating the mixture of step (a) with one or more candidate substances for improving intestinal environment and culturing the mixture; (c) analyzing the culture of step (b); Including, The screening method for substances that improve intestinal environment, wherein the composition for screening for substances that improve intestinal environment contains L-cysteine, but does not contain carbohydrates or proteins other than L-cysteine and mucin.
2. The method for screening for substances that improve intestinal environments as described in claim 1, characterized in that the composition for screening for substances that improve intestinal environments further contains mucin.
3. The method for screening for substances that improve intestinal environment according to claim 1, wherein the method is carried out under in vitro conditions.
4. 2. The method for screening for an intestinal environment-improving substance according to claim 1, wherein the culture in step (b) is carried out under anaerobic conditions for 18 to 24 hours.
5. 2. The method of claim 1, wherein analyzing the culture in the step (c) comprises analyzing the content, concentration, or type of one or more of endotoxin, hydrogen sulfide, short-chain fatty acids (SCFAs), and intestinal flora-derived metabolites contained in the culture.
6. 6. The method for screening for an intestinal environment-improving substance according to claim 5, wherein the short-chain fatty acid comprises one or more selected from the group consisting of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid.
7. The method for screening for a substance that improves intestinal environment according to claim 1 , wherein analyzing the culture in step (c) comprises analyzing changes in the type, concentration, content or diversity of intestinal microorganisms contained in the culture.
8. The method comprises: (d) comparing the analysis results of step (c) with those of a control group to select a candidate substance that increases the content of short-chain fatty acids, increases the types and contents of beneficial bacteria in the intestinal flora, decreases the contents of endotoxins and hydrogen sulfide, or decreases the types and contents of harmful bacteria in the intestinal flora. The method for screening for an intestinal environment-improving substance according to claim 1, further comprising:
Citation Information
Patent Citations
Method for obtaining microorganism by using medium containing cysteine
JP2006288272A
Cysteine granules and their use as growth stimulants of Bifidobacterium animalis lactis
JP2009542245A
Methods and compositions for improving the gut microbiota.
JP2015520176A
Probiotic and digestive enzyme compositions and methods for their preparation and use
JP2019516775A
